GENE ONLINE|News &
Opinion
Blog

Hemophilia B
CSL’s Hemgenix Wins First Gene Therapy Approval For Hemophilia In Europe
2023-02-21
Pfizer’s Hemophilia B Gene Therapy Meets Phase 3 Endpoints
2022-12-30
Hemgenix Marks Most Expensive Treatment Ever and First Gene Therapy for Hemophilia B
2022-11-22
The Transformative Potential of Gene Therapies for Hemophilia
2021-04-08
uniQure’s Inquiry Shows Hemophilia B Gene Therapy not Likely to Have Induced Liver Cancer
2021-03-30
uniQure’s Hemophilia B Gene Therapy Put on Clinical Hold by the FDA
2020-12-22
CSL Behring to Tackle Hemophilia B Using UniQure’s Gene Therapy Program
2020-06-28
LATEST
Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025
2025-05-15
Boehringer Ingelheim and Tempus AI Partner in Multi-Year Collaboration to Enhance Oncology Drug Development
2025-05-15
Study: Aligning U.S. Drug Prices with Europe Could Reduce American Life Expectancy by Six Months
2025-05-15
Tribal Leaders Warn Senators: Federal Health Funding Cuts Threaten Native American Health.
2025-05-14
Health Secretary Kennedy Retracts Parts of Agency Reorganization Plan During Combative Congressional Hearing
2025-05-14
SURMOUNT-5 Trial: Zepbound Shows Greater Weight Loss Than Wegovy
2025-05-14
ASCGT Meeting Navigates Biotech Downturn After Multi-Year Slump
2025-05-14
EVENT
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top